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ABSTRACT 
Structural and Mechanistic Investigations of Phosphothreonine Lyase Class of Enzymes 
by 
Alok Gopalkrishna Shenoy, Master of Science 
Utah State University, 2012 
Major Professor: Prof. Alvan C. Hengge 
Department: Chemistry and Biochemistry  
The phosphothreonine lyase class of enzymes represents a recently discovered set of 
enzymes that catalyze a dephosphorylation reaction. The catalysis is carried out using a unique 
elimination mechanism without any involvement of cofactors. Crystallographic studies of SpvC, 
a phosphothreonine lyase, and its mutant show that the mutation of the general catalytic acid 
does not result in any significant perturbations to the tertiary and the secondary structure of the 
protein. Using results from the structural studies and a deuterium isotope exchange experiment, 
we conclude that the reaction catalyzed by SpvC may not involve formation of a carbanion at 
the active site.  
 
(56 Pages) 
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PUBLIC ABSTRACT 
Structural and mechanistic investigations of phosphothreonine lyase class of enzymes 
Phosphorylation and dephosphorylation are a highly pervasive mechanism in biology 
that is used by the cell to modulate enzymes and proteins. The presence of a phosphate group 
can activate or deactivate an enzyme. The phosphate group is linked to a protein by a 
phosphoester bond that is known to be highly stable in cytoplasmic pH range. Thus the breaking 
and formation of these bonds need to be effected by enzymes. 
Recent discovery of the activity carried out by certain virulence related proteins (OspF 
released by Shigella and SpvC released by Salmonella) have resulted in a necessity to create a 
new class of dephosphorylating enzymes – phosphothreonine lyases.  
This class of proteins forms an important drug target against salmonella and shigella. 
The objective of our work has been to decipher the mechanism by which these effector proteins 
catalyze the dephosphorylation. Elimination reactions can be carried out by several 
mechanisms, namely E1, E2, and E1cB. Identification of the mechanism will aid in drug design. 
This report presents the results of analytical and crystallographic techniques used to study the 
mechanism of the elimination catalyzed by SpvC. 
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CHAPTER 1 
INTRODUCTION 
This report presents work on the investigation of mechanistic aspects of the reaction 
carried out by effector protein Salmonella plasmid virulence C (SpvC) with the aid of x-ray 
crystallography. SpvC, an effector protein, catalyzes an elimination of phosphate from 
phosphorylated MAPK enzyme Erk2.  
1.1 Classification of Dephosphorylating Enzymes 
Phosphorylation and dephosphorylation are universal mechanisms employed by 
biological systems to activate or deactivate enzymes. Addition (phosphorylation) and removal 
(dephosphorylation) of phosphate moiety at cytoplasmic pH require catalysis by enzymes. 
Enzymes that carry out phosphorylation can be broadly classified as kinases. Enzymes that 
dephosphorylate can either be classified as phosphatases or phosphothreonine lyases.  
Phosphatases refer to a class of enzymes that catalyze the dephosphorylation of the 
substrate by cleavage of the oxygen-phosphorus bond. This results in formation of an enzyme-
phosphate complex and the release of the substrate carrying a free hydroxyl group. The enzyme 
phosphate complex breaks down in the following step to release inorganic phosphate and 
regeneration of the enzyme active site.  
The phosphothreonine lyase class of enzymes is a set of effector proteins released by 
various pathogens like Salmonella and Shigella.  This class presently comprises of SpvC, OspF, 
and VirA. These effector proteins are known to directly aid the virulence of the pathogens. The 
activity of these enzymes involves the disruption of the MAPK pathway, preventing the 
expression of chemokine interleukin-8. Host cells use this chemokine to trigger the immune 
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response against the invading pathogen. The lack of interleukin-8 allows the pathogen to 
proliferate almost without detection through the host intestinal epithelial cells.   
1.2 Phosphothreonine lyases released by Salmonella & Shigella  
These pathogens are mainly attributed with causing dysentery and are considered a 
growing threat to humans due to fast developing antibiotic resistant strains. The past few years 
have seen over 35 widespread outbreaks of salmonellosis in U.S.A. alone,1 and affecting over 
one billion people worldwide.2 
Salmonella carries 5 genes on loci named: salmonella plasmid virulence (spv). The 
proteins expressed by these genes, namely spv R, A, B, C, and D, have been attributed to aid the 
virulence of the pathogen. While the understanding of these proteins is limited, it has been 
established that SpvB and SpvC are directly responsible for the post invasion virulence of 
Salmonella.3  
Shigella releases over 30 different effector proteins, of which the function of about five 
proteins are known.4 Of the proteins released, some have been classified under ‘Outer shigella 
protein’ (Osp).5 OspF is a protein released by Shigella, which is homologous to SpvC from 
Salmonella with over 70% sequence similarity.   
The functions of these enzymes were discovered recently and were initially mistaken to 
be dual specificity phosphatases (DuSP),6 and later correctly classified as phosphothreonine 
lyases.7 Given that these enzymes are essential for the virulence of the pathogen, 
phosphothreonine lyases form an important drug target. The mechanism of catalysis and the 
transition state structure is often used in rational drug development. The mechanism by which 
phosphothreonine lyases catalyze the elimination of phosphate is unknown. Our objective has 
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been to decipher the mechanism using analytical tools like deuterium isotope exchange and x-
ray crystallography.  
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CHAPTER 2 
LITERATURE REVIEW 
The phosphothreonine lyase class of enzymes is a recently discovered set of enzymes. 
Arbibe et al. 6 initially classified these enzymes as dual specificity phosphatases. Li et al. 7-8 
correctly deciphered the activity of OspF and SpvC, and classified these as phosphothreonine 
lyases. The results and conclusions of these publications are discussed herein. 
2.1 OspF classified as a Dual specificity phosphatase 
 
 Arbibe et al. 6 were the first group to successfully identify the substrate of 
OspF. Based on their experimental results, the authors concluded that OspF is a 
dual specificity phosphatase (DuSP) that dephosphorylates both tyrosine and 
threonine residues on Erk2. Some of their key conclusions are summarized below. 
2.1.1. Erk2 identified as the substrate of OspF 
To identify the role of OspF in vivo, the authors incubated HeLa cells  with the wild 
type (WT) and non-virulent (–VP) strains of shigella in separate experiments. Antigens 
specific to MEK1, Erk, c-Jun and their phosphorylated form pMEK1, pErk, pc-Jun 
respectively were used to analyze the pool of proteins extracted from the HeLa cell s. 
From the western blot obtained, shown in Figure 1, the authors concluded the 
following: 
 Blot showed presence of inactive MEK1, and a gradual increase in the dually 
phosphorylated pMEK1 over time. The WT strain induced the activation of 
MEK1 to pMEK1 
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 Although MEK1 was phosphorylated, Erk2 remained inactive over 180 
minutes. Other pathways involving the activation of NF-kB activation 
remained unaffected.  
 
 
Figure 1. . Immunoblot assay used to identify the substrate of OspF.6 It was noted that the WT 
induced activation of the MEK1 kinase, but the subsequent activation of Erk was absent as 
detected by western blot using antibodies specific to phosphorylated MEK1 and Erk. The 
remaining pathways were unaffected. 
This led them to believe that OspF was able to deactivate Erk2, thus altering the factors affecting 
the transcription of genes involved in immune response.  
2.1.2. OspF classified as dual specificity phosphatase 
The MAPK enzyme Erk2 has two phosphorylated residues in its active state – 
phosphotyrosine and phosphothreonine. To identify the specificity of OspF, the authors used 
immunoblot assays coupled with inhibition studies. They incubated the enzyme with its 
substrate Erk2 in presence of two inhibitors : 
 Vanadate – an inhibitor of protein tyrosine phosphatases.9 
 Okadaic acid – a picomolar inhibitor of serine/threonine phosphatase.10 
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These were then subjected to Western Blot, shown in Figure 2, with antigens specific to Erk2, 
Erk2 with phosphorylated tyrosine (pY) and Erk2 with phosphorylated threonine (pT).  
 
 
Figure 2. Immunoblot shows that OspF is inhibited by Vanadate. Also seen is a decrease in 
intensity of the phosphothreonine bands, even in presence of the inhibitors, implying OspF 
catalyzes dephosphorylation of both threonine and tyrosine residues. 
Based on the intensity of the bands of pT and pY, the authors concluded that OspF was 
inhibited by vanadate, implying specificity for pY. They also observed a decrease in intensity of 
the pT bands in presence of either inhibitor. This led them to conclude that OspF was 
dephosphorylating both threonine and tyrosine residue, and hence classified it as a dual 
specificity phosphatase.  
In the course of our literature review, we find that Arbibe et al. 6 failed to consider the 
significance of the pT-XAA1-pY motif, which was addressed by another research group discussed 
later. The skewed conclusion could be attributed to several factors, e.g. the crystal structure of 
okadaic acid bound to PP1, shown in Figure 3. Crystal structure, Figure 3A, indicates the 
positions of various active site residues with respect to the inhibitor okadaic acid. A schematic 
view of the hydrogen bonds is shown in Figure 3B, indicating all hydrogen bonds between the 
protein and the inhibitor. 
 The OspF lacks any of the conventional sequence motifs of phosphatases. This aspect of 
OspF would account for the lack of inhibition by okadaic acid. This result combined with the 
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inhibition of OspF by vanadate points towards phosphotyrosine being essential in binding of the 
substrate.  
 
 
Figure 3. A stereo view image of the picomolar inhibitor okadaic acid bound to PP1. The key 
residues involved in binding of the inhibitor to the protein are labeled.10 As seen, okadaic acid 
forms several H-bonds to various active site residues. 
2.2 Structural and mutational studies show that OspF and SpvC dephosphorylate 
threonine residue 
Li et al.7-8 addressed the shortcomings of the previous publications by using a 
biochemical approach to determine the activity and the specificity of OspF and SpvC. The group 
used a combination of analytical techniques including mass spectrometry (MS), nuclear 
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magnetic resonance (NMR) and X-ray crystallography to study the protein and the substrate. 
Based on their results, reviewed in this section, the authors concluded that OspF and SpvC 
catalyze the cleavage of phosphate by a unique elimination reaction without the involvement of 
any co-factors. 
2.2.1 OspF and SpvC dephosphorylate phosphothreonine residue on Erk2 
The authors used MS to analyze the product from the reaction between OspF and a 
synthetic phosphopeptide. Their results, shown in Figure 4, indicated a loss of 98 Da. 
Dephosphorylation by a phosphatase would result in a loss of 78 Da, hence dephosphorylation 
of both pY and pT would result in a decrease of 156 Da. The mass spectra also showed that the 
phosphate group on tyrosine was intact, implying that these enzymes were specifically targeting 
the phosphothreonine residue on the substrate.  
 
 
Figure 4. Mass Spectra indicating the loss of 98 Da as shown by Shao et al.7 The 98Da could not 
be attributed to dephosphorylation by either a PTP or a DuSP.  
To identify the product formed post reaction they subjected the reaction product to 
NMR spectroscopy. Then NMR spectrum of the product (Figure 5), when compared to that of 
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the starting material, showed a new vinylic signal. Kuipers et al.11 had attributed this signal to 
methyl dehydroalanine, formed by dehydration of threonine.  
 
Figure 5. NMR spectra comparing peptide isolated following incubation with SpvC and a 
control experiment lacking the enzyme. The vinylic signal has been attributed to ß-
methyldehydroalanine.11 
To test if their conclusion about the new vinylic product was correct, they incubated the 
product with a kinase. It was seen that the synthetic peptide was not rephosphorylated on the 
threonine residue.  
Based on the evidence gathered, they concluded that SpvC/OspF was irreversible 
dephosphorylating Erk2 by a unique elimination mechanism. Their proposed mechanism is 
schematically shown in Figure 6. A general catalytic base abstracts a proton from the alpha 
carbon of the threonine resulting in the formation of a double bond and the cleavage of the 
carbon-oxygen bond linking threonine to the phosphoester. 
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Figure 6. Reaction mechanism put forth by Shao et al. An elimination reaction resulting in a 
loss of inorganic phosphate (H2PO4
-  - 97 Da) and a proton (1 Da) which is abstracted from the 
alpha carbon atom. 
2.2.2 X-ray crystallography and kinetic studies point to K136 and H106 as the catalytic 
acid and base of SpvC, respectively  
To identify the key residues involved in the catalysis and the role of the phosphotyrosine 
on the substrate, the authors carried out crystallographic studies. X-ray crystallography showed 
a unique tertiary structure of SpvC, shown in Figure 7.  
 
 
Figure 7. Ligand-free structure of spvC WT (PDB ID: 2P1W) showing a tertiary structure similar 
to a cupped hand.  
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The structure resembled a cupped hand with two highly electropositive centers on the 
concave side. A structure with a synthetic peptide bound showed that the two phosphorylated 
resides bound to these electropositive cavities, as shown in Figure 8. 
 
 
Figure 8. Electrostatic potential surface of SpvC WT with synthetic peptide (PDB ID: 2Q8Y). 
Pocket A & Pocket B are two highly electropositive pockets that bind the phosphothreonine 
and phosphotyrosine respectively. 
The group used an alanine screen to identify the role of the residues present in the two 
electropositive pockets. Residues of OspF were mutated to alanine or arginine one by one and 
the activity of these mutants were tested with Erk2 substrate. Using Western Blot and antigens 
specific to Erk2 and pT-Erk2, the authors identified the specific mutants that were inactive or 
extremely slow to catalyze the reaction. The blot obtained by them, shown in Figure 9, showed 
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that the mutants K102R, H104A and K134A were inactive. The corresponding residues of SpvC 
were identified as K104, H106 and K136. 
 
 
Figure 9. Immunoblot assay of WT OspF and various mutants with Erk2 substrate. An alanine 
screen was used to identify key catalytic residues.8 It was seen that K102, H104 and K134 were 
inactive or extremely slow in catalyzing the reaction. 
To identify if the mutations had resulted in loss of binding affinity, the authors carried 
out a Maltose Binding Protein pull-down assay. A fusion protein of Maltose Binding Protein 
(MBP) with Erk2 was purified. The purified MBP-Erk2 was immobilized onto amylose beads. 
These beads were then incubated with OspF. The beads were then washed extensively, and the 
flow-through of these washes was subjected to SDS-PAGE and coomassie staining to 
qualitatively detect if OspF was bound to the MBP-Erk on the beads. Results obtained by the 
group are shown in Figure 10. Lane 3 and 5 are inputs and pull-down for wild type OspF 
respectively. Lane 6-8 and Lane 11-13 are inputs and pull-down for OspF K102R, H104A and 
K134A mutants, respectively.  
Based on the results obtained from the MBP pull down, they concluded that these 
mutants were capable of binding to the substrate. To identify the roles of these residues in 
catalysis the authors carried out kinetic studies to identify the pH rate profile. They found that 
the WT SpvC shows a bell shaped pH rate profile with an optimum of pH 8.5. 
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Figure S5
Fig. S5. Mutation analysis of the phosphothreonine lyase activity of OspF. (A) Equal
amounts of wild type or indicated mutant OspF proteins were added in each reaction.
Shown are the immunoblots using p-Erk (upper panel) and Erk antibody (lower panel).
(B) In vitro assay of OspF mutants using p-JNK as the substrate. (C) Kinetics analysis of
phosphothreonine lyase activity of wild type and mutants of OspF. A synthetic Erk2
phosphopeptide (DHTGFL-pT-E-pY-VATR) was used as the substrate, and the
nonradioactive molybdate dye-based phosphatase assay was carried out to measure the
release of inorganic phosphates. The Lineweaver-Burk plots were used to determine the
Michaelis-Menten kinetic parameters (kcat and Km).
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Figure 10. In-vitro interactions between recombinant Erk and OspF WT and OspF mutants. 3 
and 5 are inputs and pull-down respectively for OspF WT, Lane 6-8 and 11-13 are input and 
pull-down of OspF mutants K102R, H104A, K134A respectively.8 Pull-down shows that the 
mutants bind to the substrate with similar affinity as the wild type. 
The acidic group was determined to have a pKa of 7.6. Through mutational and kinetic 
studies of the H106 and Y158 residues, it was determined that the K136 residue was responsible 
for the acidic limb. Mutation of H106 to lysine resulted in the loss of the basic limb of the curve, 
implying that the H106 was the proton donor. The pKa of H106 was determined to be 9.4; the 
elevated values was ascribed to hydrogen bonding between Nε and the D201, which increases 
the basicity of the Nδ by stabilizing the conjugate acid form. Mutation of the Y158 did not 
inactivate the enzyme completely, indicating that this residue was not involved in the catalytic 
reaction. This, along with the mutational studies of the K104 and H106 residues, indicated that 
the K136 residue behaves as the base. K136 abstracts the proton from the alpha carbon of 
phosphothreonine. The K104 residue was deemed responsible for H-bonding with the substrate 
backbone amide carbonyl, thus reducing the pKa of the proton on alpha carbon of 
phosphothreonine. 
The authors also determined a crystal structure of SpvC K136A bound to a synthetic 
peptide. The peptide sequence derived from Erk2 contained the pT-XAA1-pY motif in the 
sequence and was co-crystallized with the inactive SpvC K136A mutant. A stereo image of the 
structure is shown in Figure 11. 
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Figure S2
Fig. S2. Interaction between OspF and Erk2 in vitro and in 293T cells.
(A) In vitro binding assay of recombinant Erk2 and OspF wild type (left
panel) and enzymatic inactive mutants (right panel). MBP or MBP-Erk2
was immobilized onto amylose beads and then incubated with the buffer
containing purified OspF protein. The beads were then washed extensively
and subjected to SDS-PAGE and coomassie staining. Lane 3 and 5 are
inputs and pulldown for wild type OspF respectively. Lane 6-8 and Lane
11-13 are inputs and pulldowns for OspF K102R, H104A and K134A
mutants respectively. (B) Association of OspF with endogenous Erk1/2,
but not MEK1 in 293T cells. Flag-HA-OspF transfected or control 293T
cell lysate  wer  subjected to a ti-Flag immunopr cipitatio  followed by
MEK1 and Erk immunoblotting analysis. (C) Coimmunoprecipitation
assay of binding between Erk2 and OspF mutants. Indicated Flag-OspF
variants were expressed and immunoprecipitated from 293T cells. The
upper and middle show the amount of Erk1/2 present in total cell lysates
and Flag immunoprecipitates respectively. Immunoprecipitated OspF and
variants are also shown in the lower panel.
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Figure 11. Stereo view of SpvC K136A, shown in light blue, bound to phosphopeptide, shown 
in orange, PDB ID: 2Q8Y. 
Based on the peptide bound structure of SpvC K136A, the WT structure and the data 
obtained by the group through mutational and kinetic studies, Shao et al. have proposed the 
mechanism for the dephosphorylation carried out my OspF and SpvC, shown in Figure 12.  
2.2.3 Structural data on phosphothreonine lyase class of enzymes is limited 
A BLAST of the sequence of SpvC results in 4 proteins: SpvC (released by Salmonella 
entrica); OspF (released by Shigella flexneri); VirA (released by Chromobacterium violaceum); 
and FL6-60 - a putative virulence protein (released by Edwardsiella tarda). A multi-sequence 
alignment of these proteins is shown in Figure 13. 
Structures obtained by various groups using X-Ray crystallography have been deposited 
in the Protein Data Bank. A summary of the structures obtained for members of the 
phosphothreonine lyase class of proteins is given in Table 1.  
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Figure 12. Proposed reaction mechanism of phosphothreonine lyase class of enzymes. The 
K136 behaves as the catalytic base that abstracts the proton followed by the H106 that 
donates a proton to the leaving phosphate group. 
 
Figure 13. Sequence alignment of SpvC, VirA, OspF and Edwardsiella putative virulence protein 
shows highly conserved residues (marked by ‘*’), specifically the catalytic acid H106, base 
K134 and several residues involved in binding of substrate 
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Table 1. Published crystal structures of enzymes comprising the phosphothreonine lyase class. 
Shown are the PDB ID's, the resolution of the structures, the space group and the ligands. 
Protein PDB ID Resolution (A) Space group Ligand 
SpvC WT 
7
 2P1W 2.30 P42 21 2 None 
SpvC WT
12
 2Z8M 2.00 P21 21 21 None 
SpvC WT 
12
 2Z8N 1.80 P21 Sulfate Ion 
SpvC WT 
12
 2Z8O 2.40 P41 2 2 Tartaric Acid 
SpvC K136A 
12
 2Z8P 1.80 P21 21 21 Dually phosphorylated synthetic peptide 
SpvC K136 A 
7
 2Q8Y 2.0 P21 21 21 Dually phosphorylated synthetic peptide 
OspF WT 
13
 3I0U 2.70 P41 21 21 (4S)-2-Methyl-2,4-Pentanediol 
VirA WT 
14
 3B06 1.40 P21 None 
 
2.2.4 The mechanism of the elimination reaction is yet to be determined 
While the efforts of the above mentioned groups have allowed us to decipher the 
activity of these enzymes, what is yet to be answered in the mechanism used by these enzymes 
is uncertain. Previous studies of elimination reactions catalyzed by enzymes have shown that 
the preferred mechanism is E1cB, involving the formation of a carbanion intermediate. 
Considering the novelty of these enzymes and the reaction catalyzed by these enzymes, 
SpvC/OspF may or may not follow this mechanism; hence other possibilities, shown in Figure 14, 
have to be considered.  
Enzyme catalysis involving elimination has been observed in various biological systems. 
One such enzyme is serine/threonine ammonia lyase, commonly known as serine/threonine 
dehydratase. These are classified as PLP-dependent enzymes due to the involvement of the PLP 
co-factor in catalysis of the reaction. This is unlike phosphothreonine lyases, wherein the 
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enzyme does not utilize any co-factor to dephosphorylate the substrate. Nonetheless, the 
reactions catalyzed by both enzyme classes involve the abstraction of a proton to form a vinyl 
group along with elimination of a leaving group. In case of the serine/threonine dehydratase, 
the leaving group is water. 
β-Elimination can be carried out by any one of the mechanisms listed below: 
1. Concerted – where in the proton abstraction and the phosphate elimination takes 
place simultaneously, shown in Figure 14.1. 
2. E1cB – Reaction involving formation of a carbanion by abstraction of proton, shown 
in Figure 14.2. This reaction mechanism is inherently stepwise and two possibilities 
arise: 
i. E1cBR: The proton abstraction is reversible, which implies the 
elimination of the phosphate is slow and hence the rate 
determining step. This indicates that k-1 is comparable or higher 
than k2. Hence the intermediate will pick up a proton to return to 
the starting material. 
ii. E1cBF: The proton abstraction is the rate-determining step, 
following which the elimination of the phosphate occurs rapidly. 
iii. This implies that k1 is significantly lower to k2, hence any 
intermediate formed converts to product. 
3. E1 – Where in the phosphate group leaves first creating a carbocation followed by 
abstraction of the proton, shown in Figure 14.3. 
In the case of concerted and E1cB mechanisms, it is possible that the elimination of the 
phosphate is irreversible. In order to account for all possibilities we depict the reaction to be 
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reversible. This report presents the body of work carried out to identify if this class of enzymes 
follows an E1cB mechanism involving the reversible formation of a carbanion at the active site.  
Analytical techniques like isotope exchange when coupled with crystal structures of the 
protein concerned provide more details of the reaction involved.15 It is essential that the 
mechanism of the beta-elimination be deduced so as to elucidate the transition state of the 
substrate-enzyme complex. This, in turn will aid inhibitor design for the enzymes. 
 
 
Figure 14. Possible mechanisms for elimination reactions shown herein schematically. 
Concerted (14.1), E1cB (14.2) and E1 (14.3) shown herein with phosphoester as starting 
material resulting in vinylic product and inorganic phosphate as products. 
To determine if the enzymes use the E1cB mechanism, we chose to use deuterium 
isotope exchange experiment. Deuterium isotope exchange experiments are used to identify the 
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rate-determining step in multi-step reversible elimination reactions wherein proton abstraction 
is involved. The incorporation of an isotopically labeled atom from the solvent into the substrate 
is often used as a method to decipher the mechanism. We used this technique to identify 
whether a carbanion intermediate is formed in the mechanism used by SpvC to catalyze the 
elimination of phosphate. This involved carrying out the reaction in a deuterated solvent 
followed by isolation of the substrate peptide. This peptide would undergo M.S. analysis to 
determine incorporation of deuterium on the c-alpha carbon.  
To carry out the above experiment, it was necessary that any carbanion intermediate 
formed at the active site did not convert to the vinylic product. Creating a mutant that could not 
protonate the leaving group would provide an enzyme in which any carbanion created at the 
active site would revert back to its protonated state by equilibrating with the solvent. Thus we 
chose the H106N mutant, which was earlier proven to be inactive.7 The H106N mutant lacked 
the histidine that was determined to be the general acid, donating a proton to the leaving 
phosphate group. The work presented herein involves structural studies of this mutant to 
determine if the mutation resulted in structural perturbations that could account for the lack of 
activity. 
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CHAPTER 3 
MATERIALS AND METHODS 
3.1 Genomics – cloning and site directed mutagenesis 
Dr. Feng Shao (of National Institute of Biological Sciences, Beijing, China) graciously 
provided us with the plasmids for MBP-OspF and MBP-SpvC, containing a GST tag. SpvC was 
cloned into a variant of prk793 vector such that the final sequence resulted in 10x histidine 
tagged SpvC with TEV cleavage site in between. 
The gene for SpvC was amplified to generate multiple copies of the original gene 
sequence using the primers SpvC Forward (SF) and SpvC Reverse (SR), given in Table 2. These 
primers also incorporated a TEV cleavage site before and a BAMHI restriction site at the end of 
the SpvC sequence respectively. The product of this PCR was isolated using electrophoresis and 
Qiagen QIAquick PCR kit. A second PCR was carried out to insert a KpnI restriction site upstream 
of the TEV cleavage site. The PCR product was digested using KpnI and BamHI restriction 
enzymes (Fermentas) and ligated into a modified prk793 vector containing 10xhistidine tag 
upstream of the maltose binding protein (MBP) domain. The plasmid from this ligation – His-
TEV-SpvC-prk793 (HP-SpvC) was purified using the protocol and materials provided in the 
Qiagen QIAquick PCR Purification Kit (Qiagen). 
The HP-SpvC plasmid was used to transform DH5-α strain of E-coli cells and plated on 
sterilized agar media plates with ampicillin and chloramphenicol. These were incubated at 37˚C 
overnight. Colonies from the plate were selected to inoculate 10mL aliquots of LB-media with 
aforementioned antibiotics. These aliquots were placed in 37˚C shakers overnight. The cells 
were pelleted and the plasmids extracted using the protocol and materials provided in QIAprep 
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Spin Miniprep kit. The solution containing the plasmids was aliquoted into eppendorf tubes and 
stored at -20˚C for future use.  
 
Table 2. Primers used to clone spvC into the prk793 variant and carry out site directed 
mutagenesis, mutating H106 to N106. The mutation (H106N) highlighted in red. 
Primer Name Primer Sequence (5’ to 3’) Description 
SpvC Forward (SF) 
GAAAACCTGTATTTTCAGGGCATGCCCATAAATAGGCCTA
ATC 
Forward primer used to amplify 
the SpvC gene. 
SpvC Reverse (SR) CGCGGATCCTTACTCTGTCATCAAACGATAAAACGG 
Reverse primer used to amplify 
the SpvC gene. 
SpvC KpnI (SKF) CGGGGTACCGAAAACCTGTAT 
Primer used to insert the KpnI 
restriction site. 
SpvC SDM Forward  
(SSF) 
GCCGGTGACAAGTTCAACATCAGTGTGCTCAGG 
Forward primer used in site 
directed mutagenesis 
SpvC SDM Reverse  
(SSR) 
CCTGAGCACACTGATGTTGAACTTGTCACCGGC 
Reverse primer used in site 
directed mutagenesis. 
 
The plasmids were used to transform BL-21 codon+ strain E-coli cells. Sterilized baffled 
flasks containing 10mL of LB media, containing 100mg/mL of ampicillin and chloramphenicol 
each, were inoculated using the transformed cells. These were shaken at 37˚C for 18 hours until 
an optical density at 600nm (OD600) of 1.5 to 1.8 was achieved. These growths were then mixed 
with 50% sterilized glycerol solution, in 4:1 ratio, and frozen at -80˚C for future use.  
The mutant SpvC H106N was created by site directed mutagenesis (SDM) using the 
protocol and materials provided in the Quick Change Lightning Kit (Agilent Technologies). The 
vectors SSF and SSR were used to insert the mutation. The plasmids were purified by Qiagen 
QIAquick PCR kit. Copies of the HP-SpvC-H106N plasmid were created using E-coli DH5-α cells, 
isolated and sequenced to confirm correct mutation. 
 The plasmids were used to transform BL-21 codon+ strain E-coli cells with ampicillin and 
chloramphenicol resistance. Sterilized baffled flasks containing 10mL of LB media, containing 
100mg/mL of ampicillin and chloramphenicol each, were inoculated using the transformed cells. 
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These were shaken at 37˚C for 18 hours until an optical density at 600nm (OD600) of 1.5 to 1.8 
was achieved. These growths were then mixed with 50% sterilized glycerol solution, in 4:1 ratio, 
and frozen at -80˚C for future use.  
3.2 Purification of the enzymes SpvC and SpvC H106N 
Four liters of 2x YT media was prepared in baffled flasks and sterilized by autoclaving. 
This was then inoculated E-Coli BL21 codon+ strain, transformed with the HP-SpvC-WT or HP-
SpvC-H106N plasmid. The broth was shaken at 37˚for up to 16 hours such that the optical 
density of the broth was noted at 1.5 OD600. 
The broth was then induced with stock solution of 100 m   sopropyl β-D-1-
thiogalactopyranoside (IPTG) such that final concentration of IPTG was 1mM. At this point the 
broth was moved from 37˚C shakers to room temperature (r.t.) shakers and left overnight (up to 
12 hours) to produce a good yield of the protein. The cells were then pelleted by centrifugation 
in a Fiberlite* F10-4x1000 LEX Rotor (Thermo Scientific), mounted on Sorvall RC-6 Plus 
Superspeed centrifuge, at 5000 rpm (9800 g) and stored at -80˚C for future use.  The buffer 
solutions used to purify His-SpvC were prepared using Nano-purified water (desalinated water) 
and adjusted to the required pH at 4˚C. Each buffer was filtered through a ilipore 20µm filter 
before use.  
The frozen stock of cell from -80˚C was thawed and warmed to 0˚C and re-suspended in 
the lysis buffer (pH 8.0 tris(hydroxymethyl)aminomethane (Tris-HCl) 20mM, Imidazole 20mM, 
NaCl 500mM, Glycerol 5% and ß-Mercaptoethanol 5mM) along with protease inhibitors 
aprotinin, leupeptin and pepstatin. The cells were broken by sonication and the debris was 
pelleted by centrifugation in SS-34 rotor (mfg. Thermo Scientific) mounted on a Sorvall RC-6 Plus 
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Superspeed Centrifuge, at 20,500 rpm (50,228 g) for 45 minutes. The supernatant was then 
incubated with 15 mL nickel resin (GE Nickel Sepharose High Performance) for a period of 2 
hours at 4˚C and placed on a rotary shaker. This was followed by separating the resin from lysate 
by filtration and re-suspension of the nickel resin in lysis buffer. The resin was washed with 4 – 6 
bed volumes of lysis buffer to ensure removal of non-specifically bound proteins and debris. 
The elution was carried out by running a gradient of elution buffer (pH 8.0, Tris-HCl 
20mM, Imidazole 500mM, NaCl 500mM, Glycerol 5% and ß-Mercaptoethanol 5mM) mixed with 
decreasing amounts of lysis buffer over a span of 120mL. The fractions were selected based on 
purity of the protein contained, determined by SDS-PAGE. The fractions were combined and 
loaded into 10kD dialysis tubing, which was suspended in TEV-cleavage buffer (pH 8.0, Tris-base 
50mM, EDTA 0.5mM, Dithiothreitol (DTT) 1mM, Glycerol 5%), for 4 hours. The buffer (TEV-
cleavage) was changed at regular intervals to eliminate imidazole from the combined fractions.  
TEV-protease, an enzyme efficient in cleaving fusion proteins at sites containing the E-
Xaa-Xaa-Y-Xaa-Q-(G/S) sequence, was used to cleave the His-tag from SpvC. During the cloning 
stage, this cleavage site was inserted at the N-terminus of the protein that the final SpvC 
sequence was left with minimal residues from the tag and the cleavage site. The dialysis tube 
containing the combined fractions and TEV-protease was incubated in the TEV-Cleavage buffer 
for approximately 8 hours. Completion of the cleavage was checked using SDS-PAGE. 
After the total cleavage of the fusion protein, it was necessary to separate the cleaved 
His-tag and TEV protease from SpvC. The contents of the dialysis tube were incubated with clean 
Ni-resin for 2 hours. SpvC, now in the flow through, was collected along with the washing of the 
Ni-Resin. SDS-PAGE was carried out to confirm the absence of the cleaved His-tag in the flow-
through.  
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The pure SpvC was then concentrated using 10kD conical tube concentrators. The final 
concentrate, 3-5 mL of clear solution containing pure SpvC, was used for 120mL Superdex Gel-
Filtration. The gel-filtration was carried out using the Superdex buffer (pH 8.5, Tris-HCl 50mM, 
NaCl 150mM, Glycerol 5%), and the fractions collected. This provided SpvC in purity exceeding 
95%, which was confirmed by SDS-PAGE. 
SpvC H106N mutant was purified using the same protocol as the WT. It was observed 
that the purification of the mutant using the above protocol afforded similar yields and purity 
exceeding 95%, confirmed using SDS-PAGE. 
3.3 Enzymology – assay protocol and materials 
Earlier work 7 had shown that the histidine residue at position 106 functions in the 
catalytic reaction as the acid, donating a proton to the leaving inorganic phosphate moiety. We 
first tested the activity of the WT enzyme to confirm the integrity of the purified protein and to 
test the optimum reaction conditions. To do this, we incubated the enzyme at various pH values 
with a synthetic peptide of the sequence H-Glu-Met-pThr-Gly-pTyr-Val-Ala-OH. The release of 
phosphate was measured by using a colorimetric assay.16 
The peptide was dissolved in the reaction buffer containing 50 mM Tris and 1 mM DTT 
pH 8.5. The same buffer was used to prepare a series of peptide dilutions in the range of 5-210 
µM. 90 µL of substrate peptide were aliquoted in the wells of flat bottom 96 well plate (Costar, 
Fisher) and 10 µL of SpvC WT were added to the final concentration of 9.4 nM to start the 
reaction. After 60 seconds the reaction was quenched by addition of 230 µL of malachite green 
assay reagent. After 15 minutes the absorbance at 625 nm was measured and converted to 
inorganic phosphate concentration via a standard curve obtained using a phosphatate standard 
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diluted with reaction buffer. Blank readings obtained from wells to which 10 µL of water were 
added in place of the enzyme were subtracted to account for non-enzymatic phosphate release.  
Calculated rates were plotted against peptide concentrations and fitted to the Michaelis-
Menten equation to obtain kinetic parameters kcat and KM of 3.2 ± 0.16 sec
-1 and 52 ± 6.0 µM, 
respectively. 
Having confirmed the activity of the WT, site directed mutagenesis was carried out 
successfully resulting in the H106N – an inactive mutant of SpvC. The purification strategy for 
the H106N mutant was same as the WT, resulting in protein of 95% purity and higher.  
To test for the E1cB mechanism, a deuterium isotope exchange experiment was carried 
out. The synthetic peptide was incubated with SpvC H106N at pH 8.5 overnight in deuterated 
water based buffer. This was then treated with trifluoroacetic acid to denature and precipitate 
the enzyme. An eppendorf concentrator 10 kDa pore size was used to remove the enzyme from 
the quenched reaction mixture. The filtrate was then lyophilized overnight and then 
resuspended in H2O. The same was carried out for a blank, wherein no enzyme was added to the 
reaction mixture. M.S. analysis of the isolated peptide showed that the experiment did not 
result in deuterium exchange on the α-carbon atom of the phosphorylated threonine.  
3.4 Crystallization of SpvC WT & H106N mutants 
The purified SpvC WT was first concentrated to 30 mg/mL (extinction coefficient of 
23045 cm-1 M-1 calculated using ProtPram of Expasy Tools 17 ), confirmed by Micro-Volume Full-
Spectrum Fluorospectrometer (Mfg. by NanoDrop Products). This concentrated protein was 
then used to manually set up vapor diffusion sitting drop trays by hand. A grid of 6x4 with 
varying concentrations of PEG and Ammonium Chloride was created to screen for the optimum 
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conditions to crystallize the WT protein. The trays were set and maintained at room 
temperature (289 K). Crystals appeared after a week and were of square bi-pyramidal shape. 
These were frozen using liquid nitrogen after soaking the crystals in the well conditions 
containing increasing quantity of glycerol (up to 15%). The optimum conditions for the WT that 
afforded reproducibility were determined as following: Protein to Well Condition ratio of 1:1, 
20% PEG 3350 (a 50% w/v solution), 0.1M Ammonium Chloride (1M stock solution).  
The mutant SpvC H106N was concentrated to 14 mg/mL of solution. A robot was used 
to screen for various conditions using kits produced by various companies like Hampton 
Research, Molecular Dimensions, etc. The Morpheus Protein Crystallization Screen18 
manufactured by Molecular Dimensions provided the conditions required to crystallize the 
protein, which was further optimized to afford reproducibility. Crystals of monoclinic shape 
were obtained which were frozen using liquid nitrogen after soaking the crystals in the well 
conditions containing increasing quantity of glycerol (up to 15%). The conditions were 
determined to be as follows: Protein to Well Condition ratio of 3:1, 20% PEG 550 MME, 10% PEG 
20000 (30% w/v solution), 0.1M Amino Acids Mix (1M stock solution mfg. by Molecular 
Dimensions), 0.1M Buffer System 1 18 at pH 6.5. 
3.5 Data collection and processing 
Data for the WT crystal were obtained by using home source generator and detector 
(Rigaku RU-200/Raxis IV++). Data was indexed and processed using d*TREK19 in the suite Crystal 
Clear. Molecular replacement was carried out using AutoMR / Phaser 20 of the Phenix suite.21 
The search model was the 1.4Å structure of SpvC (Protein Data Bank (PDB) entry 3BO6) 
complexed with sulfate ion. Refinements were carried out with Phenix Refine tool.22 The data 
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for the H106N crystal was collected at Stanford Synchrotron Radiation Lightsource (SSRL). Data 
processing was carried out on SSRL servers followed by molecular replacement using AutoMR / 
Phaser 20 of the Phenix suite.21 Refinement was carried out using Phenix Refine.22 TLS 
parameters were selected using the TLS Motion Determination server.23 In both cases Coot24 
and MolProbity25 were used to carry out model building and validation. The crystallographic 
data and the statistics are given in Table 5 (SpvC WT) & Table 6 (SpvC H106N). All figures 
depicting SpvC crystal structures were prepared using PyMol.26 The structures of SpvC WT and 
H106N mutant have been submitted to PDB under the ascension IDs 4HAH and 4H43, 
respectively.  
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CHAPTER 4 
RESULTS 
4.1 Crystallography 
The two structures obtained have been submitted to the Protein Data Bank (PDB) under 
the ascension IDs 4HAH (SpvC WT) and 4H43 (SpvC H106N mutant). The wild type was 
crystallized under conditions previously published,7 and then further optimized for 
reproducibility. The SpvC H106N mutant was initially crystallized using Morpheus Protein 
Crystallization Screen (mfg. Molecular Dimensions) with the aid of ARI Crystal Gryphon robot. 
The two structures have been compared to previously published structures to determine the 
structural integrity of the mutant. The statistical data for SpvC WT (4HAH) and SpvC H106N 
(4H43) have been presented in Table 3. 
4.2 Structural aspects of SpvC WT (4HAH) as compared to the previously published 
structure (2Z8M) 
The structure used to verify the integrity of the crystallized SpvC WT was a 2Å ligand-
free structure (PDB ID: 2Z8M).12 The structures were overlapped in PyMol26 to compare the 
tertiary and secondary structures of the two ligand-free proteins. As shown in Figure 15, the 
tertiary structure of the two proteins closely resembled each other in terms of positions of 
loops, helices and β-sheets. PDBeFOLD27 was used to compare the structures by assessing the 
overlap of the backbone and the side chains of all the amino acids present in each of the 
structures. The result (RMSD = 0.16) is presented in terms of root mean square deviation 
(RMSD). The lower the RMSD, the better the overlap of the two structures. 
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Table 3. Data collection and refinement statistics for SpvC WT. 
Values in brackets correspond to those in outer resolution shell. 
Data Collection SpvC WT SpvC H106N 
Beamline Homesource SSRL 
Wavelength (Å) 1.5418 0.97591 
Resolution Range (Å) 32 – 1.80 50 – 2.3 
Outer Shell (Å) 1.86 – 1.80 2.38 – 2.30 
No. of Reflections   
Total 331429 405022 
Unique 45887 35594 
Average Redundancy 7.22 (4.35) 11.4 (11.5) 
Mean I/ σ ( ) 9.0 (2.5) 33.655 (4.4) 
Completeness (%) 98.4 (86.8) 99.8 (99.5) 
Rsym (%) 0.107 (0.485) 0.076 (0.614) 
Space Group P212121 P32 
Unit Cell Dimensions (a, b, c) (Å) 64.53   71.91   106.49 70.989   70.989   142.972  
Refinement 
 
Rwork / Rfree (%) 0.1935 / 0.2310 0.1749 / 0.2161 
Atoms in structure   
Protein 3496 3478 
Water 468 191 
Average B-factors (Å
2
)   
Protein 22.01 46.88 
Water 30.91 47.3 
Root mean square deviation   
bonds (Å) / angles (degrees) 0.007 / 1.024 0.007 / 0.979 
Protein geometry   
Ramachandran Outliers (%) 0.00 0.0 
Ramachandran Favored (%) 99 98.6 
Rotamer Outliers (%) 0.5 0.52 
PDB Entry 4HAH 4H43 
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Figure 15. Tertiary structure of SpvC WT, PDB ID 2Z8M in purple, when compared to our 
structure of ligand-free SpvC WT, 4HAH in teal, shows that the structures are very similar, with 
a RMSD of 0.16 for 215 residues. 
A close inspection of the structure 4HAH compared to 2Z8M showed that crucial 
residues important to catalysis are overlapping, as shown in Figure 16. 
In addition to the catalytic site, SpvC has another binding pocket for the second 
phosphoryl group (pY) of the enzyme’s native bis-phosphorylated substrates.  The residues in 
this pocket responsible for binding phosphotyrosine were also found to have retained their 3-
dimensional positions when compared to 2Z8M, as shown in Figure 17. 
To support the structural analysis, a chemical assay was carried out to confirm the 
ability of the purified enzyme to dephosphorylate the substrate. This was done using a 
truncated peptide, containing the pT-XAA-pY motif, H-Q-M-pT-G-pY-V-A-OH. The enzyme on 
incubation with the peptide at pH 8.5 resulted in release of inorganic phosphate, which was 
detected using phosphomolybdate assay.16 Having confirmed the activity of the WT, we pursued 
the crystallization of the H106N mutant, previously found to be inactive7 and used by us in a 
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deuterium isotope exchange experiment designed to probe the chemical mechanism. Because 
this experiment resulted in no deuterium isotope exchange, the goal of the structural study was 
to investigate if the mutation resulted in structural perturbations that would prevent the ability 
of the protein to bind to the substrate. 
 
 
Figure 16. Comparisons of the positions of the active site residues of SpvC WT in the structure 
4HAH (teal) obtained in this work, compared with a previously reported structure, 2Z8M, in 
purple. It is clearly seen that the residues from the two structures superimpose each other. 
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Figure 17. pY binding pocket residues compared between structures obtained through this 
work against previously published structures. Overlaid above are 4HAH, in teal, and 2Z8M, in 
purple. 
 
4.3 Structural aspects of SpvC H106N (PDB ID: 4H43) 
The H106N mutant has been reported previously, but to date no structure exists in the 
Protein Data Bank. In order to correctly interpret the results of mechanistic investigations with 
this mutant, an x-ray crystal structure of the protein was necessary. This would allow us to 
determine if the mutation of the wild-type protein resulted in structural perturbations that 
might affect the binding.  
Sequencing confirmed the presence of the correct mutation following which the purified 
enzyme was used to obtain crystals in sitting-drop experiments set up by hand.  PDBeFOLD27 
was used to compare this crystal structure, PDB ID 4H43, with the SpvC WT structure, PDB ID 
4HAH. Calculations showed a RMSD of 0.33Å. Tertiary structures were compared in PyMol,26 as 
shown in Figure 18. 
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The mutant was aligned with the WT to compare the positions of active site residues, as 
shown in Figure 19. The conclusion is that the mutation of the histidine residue on position 106 
to asparagine does not affect the secondary or tertiary structure of the protein. This supports 
the conclusions reported from the kinetic assay work that the lack of activity of SpvC H106N is 
due to the mutation of the catalytic general acid, and not due to structural deformations 
induced by the mutation. 
 
 
Figure 18. Shown above the structural alignment of SpvC WT (4HAH), in teal, on SpvC H106N 
(4H43) in green. The RMSD for 3D overlap of the two structures for 215 residues is 0.33. 
The structural alignment of the WT and the H106N mutant was used to verify the 
position of residues involved in the two pockets which bind the phosphorylated tyrosine and 
threonine residues, shown in Figure 20. It was seen E215 was displaced by 1.8Å and R220 was 
displaced by 1.4 Å. It has been determined that the H215 residue forms H-bonds with the 
backbone of the substrate. This segment of the protein, a loop carrying the catalytically 
important residue R220, seems to be extremely mobile with a high B-factor as compared to the 
average B-factor of the whole structure.  
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Figure 19. Active site of SpvC H106N (PDB ID 4H43), in green, structurally aligned to SpvC WT 
(PDB ID: 4HAH), in teal. The mutation H106  N106 has been labeled. 
 
Figure 20. Recognition site of SpvC H106 (PDB ID: 4H43), in green, aligned with SpvC WT (PDB 
ID: 4HAH), in teal. This site is known to bind to the phosphorylated tyrosine on the substrate. 
Residue E215 is displaced by 1.8 Å, attributed to the mobile loop it is a part of.  
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B-Factors provide a numerical representation of the electron density detected at 
specific positions during the x-ray diffraction. High B-factor values imply high mobility of the 
residues, hence providing a reduced electron density. A study of the B-factors of the residues 
forming the R220 loop showed that the backbone and the side chains for the residues were 
significantly higher than the average B-factor of 46.9, as shown in Table 5. Average B-factors 
were calculated using StrucTools.28 This implies that the loop carrying R220 and E215 residues is 
mobile. 
Figure 21 shows that the loop carrying the two residues R220 & E215 undergoes a 
conformational change upon binding of the substrate. The R220 residue forms H-bonds with the 
phosphate moiety on the phosphothreonine of the substrate. The E215 backbone amide N-H 
forms H-bonds with the carbonyl of the backbone amide of the phosphotyrosine of the 
substrate backbone. The mobility of the loop allows a conformational change to occur upon 
substrate binding, bringing the respective residues in close proximity. 
 
 
Table 4. Average B factors of side chains and backbone of several residues of SpvC H106N 
(4H43) that form the movable loop. It is seen that the residues, which form the loop, have 
high b-factors as compared to the overall b-factor of the protein (46.9). 
Residue (Amino Acid) Side Chain Backbone 
215 (E) 78.74 61.28 
216 (L) 78.11 77.0 
217 (R) 78.79 89.45 
218 (S) 108.54 104.64 
219 (G) 0.0 108.75 
220 (R) 115.83 100.50 
221 (D) 105.99 86.25 
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The respective positions of the movable loop in the WT and the H106N mutant are 
compared in Figure 22. It is seen that they closely resemble each other. A comparison using 
Secondary Structure Matching (SSM) 27a showed that residues of the two loops had a Q-Score of 
0.90, implying a close overlap of the two loops. 
The structures of SpvC WT (PDB ID 4HAH) and SpvC H106N (PDB ID 4H43) closely 
resemble each other in the catalytic site, the pY binding site and the positions of the loop 
carrying the R220 and E215 residues. The H106N structure shows a high mobility of the loop, 
which we believe is responsible for the need for crystallization conditions different than that of 
SpvC WT. No significant deformations to the structure of the SpvC are induced due to the H106N 
mutation.  
 
Figure 21. The movable loop of ligand-free SpvC WT (4HAH), in teal, aligned to SpvC K136A 
(2Q8Y) in light purple, with substrate bound, in orange. Upon substrate binding the R220 
carrying loop changes its conformation to the closed form, such that the R220 is placed in 
proximity to the phosphothreonine residue (P219) of the substrate. The change also positions 
E215 in close proximity to the amide carbonyl of the substrate backbone. 
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Figure 22. The movable loop carrying the R220 and E215 residues compared between the 
structures of SpvC WT shown in light blue and the SpvC H106N, shown in green. Residues 200 
to 225 compared using SSM 27a indicated a Q-score of 0.90 for all 26 residues.  
 
 
 
 
 
 
 
 
 
 
 
 
R220
E215
 38 
CHAPTER 5 
DISCUSSION 
5.1 Results indicate the absence of a carbanion intermediate 
The objective of the presented research was to provide structural information to assist 
in the interpretation of kinetics and mutagenesis experiments about the type of mechanism 
followed by phosphothreonine lyases. As described earlier, elimination reactions can take any 
one of the several pathways – E1, E1cBR, E1cBF and concerted, mechanisms of which were 
shown in Figure 14. The research presented herein seeks to support the findings of the 
aforementioned deuterium isotope exchange experiment with structural data. The objective 
behind the research was two-fold:  
 Determine the crystal structure of SpvC WT purified using a previously unpublished 
protocol. 
 Purify the H106N mutant and determine the structures. Compare the structures of the 
wild type (4HAH) and the H106N mutant (4H43) to previously published structure 
(2Z8M), with the goal of determining if the mutation results in any structural 
perturbation that might affect substrate binding or catalysis. 
The comparison of the two structures against previously published active WT structures 
allows us to verify the integrity of the proteins purified and crystallized in this study. The 
inactivity of the H106N mutant may arise due the structural changes induced due to the 
mutation, which might affect the binding of the substrate. This would result in the observed lack 
of deuterium exchange at the expected C-α, thus giving us a false positive result. In addition, the 
previously reported kinetic experiments with this mutant concluding that H106 is the catalytic 
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general acid would be invalidated if significant structural perturbations were found. Our work 
seeks to eliminate this possibility and support the deuterium exchange experiment in 
eliminating the E1cB mechanism of the various possibilities discussed earlier.  
To test for the E1cB type of mechanism, it was necessary to create mutant that lacked 
the catalytic acid, responsible for donating a proton to the leaving phosphate group. The H106 
residue was identified as the catalytic acid previously and was successfully created using site 
directed mutagenesis. Another lab member, Vyacheslav Kuznetsov, carried out deuterium 
isotope exchange experiments using this mutant.  
Since the mutant lacked the catalytic acid, the reaction would remain incomplete. In the 
case of an E1cB mechanism being employed by SpvC (Equation 2, Table 1) depending on the 
rate-limiting step, different results would be observed. As stated earlier, it was our objective to 
test for the formation of a carbanion intermediate at the active site. An incomplete reaction due 
to lack of a catalytic acid would provide sufficient time for the reverse reaction, wherein the 
deprotonated substrate would pick up a deuterium atom from the solvent (buffered D2O).  
The substrate was incubated with the mutant enzyme in buffered D2O. The substrate 
was then isolated and analyzed using mass spectrometry to determine the incorporation of 
deuterium on he C-α. The presence of deuterated C-α would indicate that a carbanion 
intermediate forms, and that the enzyme is capable of stabilizing such a species in the native 
reaction.  Such a carbanion intermediate might undergo elimination rapidly (in other words, 
carbanion formation is rate-determining) or slowly, with elimination rate determining.  If the 
first possibility is the case, then deuterium exchange might be observed even with the wild type 
enzyme.  The H106N mutation hinders the elimination step, thus if the enzyme does form a 
carbanion intermediate, its only path is in the reverse direction, reprotonation by an 
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exchangeable proton (or deuteron) from the solvent.  If, on the other hand, a concerted 
elimination reaction takes place with no carbanion intermediate, then no deuterium exchange 
will be observed even in the H106N mutant. 
The lack of deuterium exchange at the C-α presents us with one of two possibilities – 
 That SpvC does not dephosphorylate the phosphothreonine residue using 
carbanion intermediate, hence the lack of deuterium exchange at the C-α. 
 The mutation of the H106N residues created a structural anomaly that renders 
the enzyme incapable of binding to the substrate peptide, thus resulting in lack 
of deuterium exchange.  
Using the same purification strategy as the wild type SpvC, we successfully purified the SpvC 
H106N mutant. It was found that the mutant enzyme on incubation with the synthetic peptide 
did not release inorganic phosphate, as determined by phosphomolybdate assay16. Since we had 
created a mutant that altered an active site residue, it was necessary to verify the structural 
integrity of the purified mutant.  
As described in the previous chapter, X-ray crystallography was used to determine the 
structure of our WT structure (4HAH) and mutant (4H43). The wild type structure obtained in 
this project was compared with the previously published structure of ligand free SpvC WT 
(2Z8M). It has been confirmed that the new structures retain their structural integrity despite 
the use of new purification and crystallization protocols. Our experimentation has shown that 
the SpvC WT, purified and crystallized by in this study, is active and is able to bind to the 
substrate effectively. Structural studies of SpvC H106N mutant have shown that the WT and the 
H106N mutant structure have no significant structural differences. The detailed comparison of 
the mutant with the wild type structures described in the preceding section reveal no structural 
changes in H106N mutant that would significantly affect binding of the substrate. While the 
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present structural investigation does not directly measure the ability of the H106N mutant to 
bind the substrates used in either the kinetics or deuterium exchange experiments, the present 
results document the lack of any structural consequences of the mutation. 
The structural data obtained in this project therefore supports the conclusion that the 
lack of deuterium on the phosphopeptide implies that the enzyme class does not utilize the 
mechanism involving the formation of a carbanion (E1cB). While there exists the possibility of 
several other mechanisms, through our presented work, we have successfully eliminated the 
E1cB type reaction mechanism. These structural results also support the conclusion of an earlier 
study that the lack of activity of the histidine mutant implicates it as a catalytic residue,8 and is 
not due to structural perturbations.   
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CHAPTER 6 
CONCLUSION 
Phosphothreonine lyases form a class of enzymes that are relatively new and are of 
great significance in development of drugs against disease causing pathogens like Salmonella 
and Shigella. Our objective has been to expand the understanding of this class of proteins by 
understanding the mechanism used by the proteins to carry out dephosphorylation.  
Through our work we have gained some knowledge about the mechanistic aspects of 
the enzyme SpvC, which we believe will aid the scientific community in understanding 
phosphothreonine lyases. We have: 
 Created a new plasmid carrying the protein with 10x His-tagged recombinant SpvC with 
TEV cleavage site. This creates a recombinant SpvC with only one residue from the 
cleavage site on the N-terminus as compared to previously published recombinant SpvC. 
The presence of fewer amino acids from tags and cleavage sites results in lesser packing 
irregularities during crystallization. 
  Developed a new and easily reproducible purification protocol that results in OspF and 
SpvC of purity greater than 95%. 
 Crystallized and solved the previously unreported structure of the SpvC H106N mutant 
In doing so, we have verified that the H106N (PDB ID 4H43) mutant retains all structural 
aspects of the active wild type protein (PDB ID 4HAH) with only minor differences in the 
position of the movable R220 loop. 
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 Results from our deuterium isotope exchange experiment indicate that 
phosphothreonine lyase catalyzes the dephosphorylation without the formation of a 
carbanion intermediate. 
Our work allows us to narrow down the mechanistic possibilities that can be involved in 
the elimination of the phosphate group by phosphothreonine lyases. This will aid future 
research in developing mechanism-based inactivators of phosphothreonine lyases.  
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